 Imatinib Mesylate
"Imatinib Mesylate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
| Descriptor ID |
D000068877
|
| MeSH Number(s) |
D02.065.277.456 D02.241.223.100.100.435 D02.455.426.559.389.127.085.465 D03.383.606.405 D03.383.742.349
|
| Concept/Terms |
Imatinib Mesylate- Imatinib Mesylate
- Mesylate, Imatinib
- Imatinib Methanesulfonate
- Methanesulfonate, Imatinib
Imatinib- Imatinib
- Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
|
Below are MeSH descriptors whose meaning is more general than "Imatinib Mesylate".
Below are MeSH descriptors whose meaning is more specific than "Imatinib Mesylate".
This graph shows the total number of publications written about "Imatinib Mesylate" by people in this website by year, and whether "Imatinib Mesylate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 5 | 5 | | 2008 | 0 | 6 | 6 | | 2009 | 0 | 8 | 8 | | 2010 | 0 | 4 | 4 | | 2012 | 0 | 3 | 3 | | 2013 | 0 | 3 | 3 | | 2014 | 0 | 4 | 4 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 1 | 2 | | 2018 | 0 | 1 | 1 | | 2021 | 1 | 2 | 3 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Imatinib Mesylate" by people in Profiles.
-
Galkin A, Sitapara R, Clemons B, Garcia E, Kennedy M, Guimond D, Carter LL, Douthitt A, Osterhout R, Gandjeva A, Slee D, Salter-Cid L, Tuder RM, Zisman LS. Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. Eur Respir J. 2022 12; 60(6).
-
Fogueri U, Charkoftaki G, Roda G, Tuey S, Ibrahim M, Persaud I, Wempe MF, Brown JM, Thurman JM, Anchordoquy TJ, Joy MS. An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis. Drug Deliv Transl Res. 2022 06; 12(6):1445-1454.
-
Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021 08; 9(8):502-514.
-
Affandi T, Ohm AM, Gaillard D, Haas A, Reyland ME. Tyrosine kinase inhibitors protect the salivary gland from radiation damage by increasing DNA double-strand break repair. J Biol Chem. 2021 Jan-Jun; 296:100401.
-
Gore L, Kearns PR, de Martino ML, De Souza CA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, Rabin KR, Sacchi M, Swanink R, Zwaan CM. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018 05 01; 36(13):1330-1338.
-
Riva B, De Dominici M, Gnemmi I, Mariani SA, Minassi A, Minieri V, Salomoni P, Canonico PL, Genazzani AA, Calabretta B, Condorelli F. Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of ?-catenin and mTORC1/2. Oncotarget. 2016 Dec 06; 7(49):81555-81570.
-
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21.
-
Rizzo AN, Sammani S, Esquinca AE, Jacobson JR, Garcia JG, Letsiou E, Dudek SM. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2015 Dec 01; 309(11):L1294-304.
-
Afghahi A, Sledge GW. Targeted Therapy for Cancer in the Genomic Era. Cancer J. 2015 Jul-Aug; 21(4):294-8.
-
Giannou AD, Marazioti A, Spella M, Kanellakis NI, Apostolopoulou H, Psallidas I, Prijovich ZM, Vreka M, Zazara DE, Lilis I, Papaleonidopoulos V, Kairi CA, Patmanidi AL, Giopanou I, Spiropoulou N, Harokopos V, Aidinis V, Spyratos D, Teliousi S, Papadaki H, Taraviras S, Snyder LA, Eickelberg O, Kardamakis D, Iwakura Y, Feyerabend TB, Rodewald HR, Kalomenidis I, Blackwell TS, Agalioti T, Stathopoulos GT. Mast cells mediate malignant pleural effusion formation. J Clin Invest. 2015 Jun; 125(6):2317-34.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|